

Target Product Profile - Gonorrhea Vaccine

Variable	Minimal Requirement	Ideal Requirement
Primary Product Indication	Prevention of genital urinary-tract gonorrhea	Prevention of all forms of gonorrhea, including disseminated gonorrhea
Organisms Covered	<i>N. gonorrhoeae</i> , with coverage of 70% of clinical isolates	<i>N. gonorrhoeae</i> , with coverage of 90% of clinical isolates
Target Population	Teenagers/adults >14 years in LMICs	Teenagers/adults >14 years in LMICs
Modality	Quantitatively optimized composition	Quantitatively optimized composition
Protection Duration	2 years	5 years
Delivery Mode	IM	IM
Dosage Form	Single dose vial	Multi-dose vial/syringe
Regimen	Two administrations	One administration
Efficacy	50%	70%
Risk/Side Effects	Local, mild AEs only	Local, mild AEs only
Stability	1 year at 4C	1 month at 37C
Cost	1-5\$/dose	<1\$/dose
Specific Population Claims		HIV-infected populations